UBS Maintains Buy on CVS Health, Lowers Price Target to $107
UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $118 to $107.
Share
Why It Matters
A big bank analyst still likes CVS Health, but thinks it's worth less money now. When experts lower their price guesses, it means they see some bumps ahead for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.